Skip to main content
. 2022 Sep 26;13:5654. doi: 10.1038/s41467-022-32867-z

Table 1.

Clinical characteristics of SARS-CoV-2-infected patients

All patients: 69 % Critical n: 27 % Severe n: 14 % Mild n: 28 %
Age [years]

61

(24–90)

-

63

(39–79)

-

76

(31–90)

-

45

(24–65)

-
Female 24 34.8 5 18.5 3 21.4 16 57.1
Male 45 65.2 22 81.5 11 78.6 12 42.9
Comorbidities
Hypertension 21 51.2 12 44.4 9 64.3 n.a. -
Cardiovascular disease 14 34.1 5 18.5 9 64.3 n.a. -
Pulmonary disease 6 14.6 2 7.4 4 28.6 n.a. -
Chronic kidney disease 6 14.6 1 3.7 5 35.7 n.a. -
Diabetes 10 24.4 6 22.2 4 28.6 n.a. -
Malignancy 8 19.5 4 14.8 4 28.6 n.a. -
none 6 14.6 6 22.2 0 0 n.a. -
Diagnostic markers
Interleukin-6 [pg/ml] 1012.8 -

1452.1

(3774.6)

-

46.1

(26.8)

- n.a. -
Procalcitonin [ng/ml] 7 -

9.9

(21.9)

-

0.17

(0.11)

- n.a. -
C-reactive protein [mg/l] 128.1 -

162.2

(75.8)

-

65.3

(47.1)

- n.a. -
Lactate dehydrogenase [U/l] 800.97 -

1061.7

(1976.3)

-

305.6

(78.3)

- n.a. -
Complications
Bacterial superinfection 16 39 11 40.7 5 35.7 n.a. -
Treatment
Hydroxychloroquine, Ritonavir + Lopinavir (Kaletra) 24 58.5 18 66.7 6 42.9 n.a. -
Fatal outcome
Total 11 26.8 10 37 1 7.1 n.a. -

Patients were categorized as either severely (hospitalized on regular ward, requiring O2 supplementation, n = 14), critically (intensive care unit admission and in need of invasive mechanical ventilation, n = 27) or mildly diseased (non-hospitalized, n = 28). Diagnostic markers are depicted as mean and standard deviation (SD) (in brackets) of all analyzed laboratory parameters obtained 13–25 days post symptom onset for critically and severely diseased patients. Percentage [%] is indicated. n.a.: not available. Source data are provided as a Source Data file.

HHS Vulnerability Disclosure